Overview


According to FutureWise analysis the market for Transmucosal Drug Delivery Devices is expected to register a CAGR of 6.40% from 2024-2032.

Transmucosal drug delivery is a unique method of drug administration that involves the buccal, nasal, vaginal, and urethral canals. In recent years, technological developments and an increasing focus on research and development to examine innovative delivery systems for medication in humans have established the market for transmucosal drug administration. The transmucosal drug delivery system provides a number of advantages over traditional drug administration routes, making it a lucrative market for companies involved in the value chain. One of the most significant benefits of transmucosal drug delivery is that it permits pharmaceuticals to bypass the natural defense mechanism. Many drugs may become ineffective when delivered through different routes due to high stomach acidity or first-pass metabolism.

Because the mucosal cavity lining has a porous membrane with a plentiful supply of blood vessels, medications provided through these pathways can be absorbed directly into the circulatory system and transferred to the target sites. During the forecast period, the worldwide transmucosal medication delivery market is expected to develop due to an increase in the popularity of home health care. Furthermore, the worldwide transmucosal drug delivery market is expected to be propelled in the near future by the rapidly expanding incidence of chronic ailments such as gastrointestinal, respiratory, and autoimmune disorders.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Transmucosal Drug Delivery Devices Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Transmucosal Drug Delivery Devices Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  •  Teva Pharmaceutical Industries Ltd.
  •  Slan Medicinal Holdings LTD
  •  MMB Healthcare, LLC.
  •  BioDelivery Sciences International, Inc.
  •  Novartis AG
  •  Bristol-Myers Squibb Company
  •  Bayer AG
  •  Johnson and Johnson Private Limited
  •  Antares Pharma
  •  BD
  •  3M
  •  Pfizer Inc.
  •  Boehringer Ingelheim International GmbH.
  •  Abbott
  •  Endo International plc
  •  B. Braun Melsungen AG
  •  Mylan N.V.
  •  Baxter
  •  GlaxoSmithKline plc
  •  Acrux Limited
  •  Echo Pharmaceuticals B.V.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  •  Passive Transdermal Drug Delivery
  •  Active Transdermal Drug Delivery

By Drug Type

  •  Buccal Tablets
  •  Oral Sprays
  •  Sublingual Films and Wafers
  •  Gels
  •  Medicated Confectionery

By Indication

  •  Pain Management
  •  Addiction Treatment
  •  Hormonal Therapies
  •  Others

By Route of Administration

  •  Buccal
  •  Nasal
  •  Vaginal
  •  Urethral

By End User

  •  Academic and Research Institutes
  •  Pharmaceutical and Biotechnology Companies
  •  Diagnostic Laboratories
  •  Hospitals

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Transmucosal Drug Delivery Devices Market By Type, By Drug Type, By Indication, By Route of Administration, By End User and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Transmucosal Drug Delivery Devices Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Transmucosal Drug Delivery Devices Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Transmucosal Drug Delivery Devices Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Transmucosal Drug Delivery Devices Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Passive Transdermal Drug Delivery
        2. Active Transdermal Drug Delivery

  • 8.   Transmucosal Drug Delivery Devices Market, By Drug Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Buccal Tablets
        2. Oral Sprays
        3. Sublingual Films and Wafers
        4. Gels
        5. Medicated Confectionery

  • 9.   Transmucosal Drug Delivery Devices Market, By Indication Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Pain Management
        2. Addiction Treatment
        3. Hormonal Therapies
        4. Others

  • 10.   Transmucosal Drug Delivery Devices Market, By Route of Administrations Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Buccal
        2. Nasal
        3. Vaginal
        4. Urethral

  • 11.   Transmucosal Drug Delivery Devices Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Academic and Research Institutes
        2. Pharmaceutical and Biotechnology Companies
        3. Diagnostic Laboratories
        4. Hospitals

  • 12.   North America Transmucosal Drug Delivery Devices Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 13.   Latin America Transmucosal Drug Delivery Devices Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 14.   Europe Transmucosal Drug Delivery Devices Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 15.   Asia Pacific Transmucosal Drug Delivery Devices Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 16.   Middle East and Africa Transmucosal Drug Delivery Devices Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Teva Pharmaceutical Industries Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Slan Medicinal Holdings LTD
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. MMB Healthcare, LLC.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. BioDelivery Sciences International, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol-Myers Squibb Company
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson and Johnson Private Limited
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Antares Pharma
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. BD
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. 3M
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Pfizer Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
         13. Boehringer Ingelheim International GmbH.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. Abbott
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Endo International plc
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. B. Braun Melsungen AG
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Mylan N.V.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Baxter
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. GlaxoSmithKline plc
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Acrux Limited
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
         21. Echo Pharmaceuticals B.V.
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients